Biopharma, biotech, and academic researchers are on the front lines of discovering treatments and cures to the world’s most complicated diseases and widespread public health threats. Now more than ever — as you begin to return to the lab — we are here to support you in your relentless pursuit of cures. Tap into our…
With so many commercial characterized immune cell, leukapheresis, and apheresis products available in one place, it can be difficult to determine the best fit for your research and development needs. The big decisions immune cell and biomaterial buyers face comes down to two factors: Fresh or frozen product? By the vial or full leukopak? This…
Following the successful and anticipated launch of our Anti-ProInsulin T Cells for PI-1 and PI-3 last year, researchers like you have asked us to develop additional antigen-specific T cell lines for diabetes research. We are excited to announce our latest cell line for diabetes autoimmunity research, the Anti-GAD65 T Cells! View Anti-GAD65 T Cells Lot…
New brand and expansion reflect the company’s mission to support the development and delivery of tomorrow’s treatments and cures. MEMPHIS, TN and BOTHELL, WA – May 12, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today…
Welcome customers, partners, and colleagues to the new Cellero website! On behalf of Key Biologics and Astarte Biologics, I’d like to introduce you to our new brand. My name is Jeff Allen, CEO of Cellero. Over the past two years, the Key Biologics and Astarte Biologics teams have been working tirelessly to combine two valued,…
Launches new program to supply blood products from COVID-19 convalescent donors LOWELL, MA and MEMPHIS, TN – April 29, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today announced the launch of an IRB-approved initiative to…
Recovered patients carrying SARS-CoV-2 antibodies are being collected under Key Biologics newest IRB-Approved protocol to help drive therapeutic agent & vaccine development. Responding to the FDA’s call-to-action for convalesced plasma & other blood products collection, and to meet mounting requests from institutional & biopharmaceutical researchers in need of premium cells, Key Bio’s COVID-19 protocol is active in…
The Catalogue of Somatic Mutations in Cancer (COSMIC) is the world’s largest and most comprehensive resource for exploring the impact of somatic mutations in human cancer. Why We Love COSMIC 1. The website is an easy, one-stop reference for all information about specific genes and mutations. 2. The cancer browser shows mutations that are…
Key Biologics (A Cellero Company) is open and maintaining normal operations. To ensure that we can maintain normal operations as the spread of COVID-19 continues, we have activated our business continuity plans. Our management teams are focused on overseeing our response to the evolving situation. COVID-19 has not impacted Key Biologics’ ability to deliver any…
Assessing an individual’s eligibility to safely donate blood products has always been and remains our highest priority. To accomplish this, we use a several stepped process, learn more about our process below. Key Biologics (A Cellero Company) has transitioned over the past two plus decades from a department within an FDA-registered community blood center providing…